Application of harmine derivative to preparation of drugs for treating cystic echinococcosis

Abstract

The invention relates to the technical field of application of a harmine derivative, and particularly discloses the application of a harmine derivative to preparation of drugs for treating cystic echinococcosis for the first time. In-vitro pharmacodynamic experiment data prove that the harmine derivative can reduce the survival rate of echinococcosis granulosis cyst remarkably; In-vivo pharmacodynamic experiment data prove that the efficacy of the harmine derivative and the efficacy of albendazole are similar in treating cystic echinococcosis; in-vitro-and-vivo safety evaluation experiment data prove that the toxicity of the harmine derivative is lower than that of a harmine monomer with cystic echinococcosis resisting activity. Therefore, a new approach is provided for treating cystic echinococcosis.

Description

technical field [0001] The invention relates to the application technical field of dehydrohaeline derivatives, and relates to the application of a dehydrohaeline derivative as a medicine for treating cystic echinococcosis. Background technique [0002] Hydatid disease, also known as echinococcosis, is a serious zoonotic parasitic disease caused by the parasitic larvae of Echinococcus tapeworm in the human body, and 95% of the cases are larval cysts of Echinococcus granulosus Cystic echinococcosis in humans. The disease is distributed globally. Seven provinces (autonomous regions) including Xinjiang, Tibet, Ningxia, Qinghai, Gansu, Inner Mongolia, and Sichuan in western my country are high-incidence areas, causing economic losses of more than 3 billion yuan every year. It is one of the main causes of poverty and return to poverty due to illness, and it is also a serious public health problem that has attracted much attention. In 2006, the disease was included in the national ...

AI Technical Summary

Problems solved by technology

[0007] The present invention provides a dehydrohaeline derivative used as a drug for treating cystic echinococcosis, which overcomes the above-mentioned deficiencies in the prior art, and can effectively solve the problem of treating cystic echinococcosis with dehydrohaeline monomer. The toxicity of the disease exists; the present invention discloses for the first time the application of dehydrohalamine derivatives as a drug for the preparation of cystic echinococcosis; the in vitro pharmacodynamic experiment data show that dehydrohalamine derivatives can significantly reduce The survival rate of Echinococcus granulosus; the in vivo pharmacodynamic experimental data show that dehydrohaeline derivatives are equivalent to albendazole in the treatment of cystic echinococcosis; the in vivo and in vitro safety evaluation experimental data show that dehydrocameline derivatives The toxicity of sacarpine derivatives is less than that of dehydrohalamine monomer with anti-cystic echinococcosis activity, thus providing a new way for the treatment of cystic echinococcosis

Images